GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (STU:KK3A) » Definitions » Buyback Yield %

Cytokinetics (STU:KK3A) Buyback Yield % : -11.57 (As of Sep. 21, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cytokinetics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cytokinetics's current buyback yield was -11.57%.


Cytokinetics Buyback Yield % Historical Data

The historical data trend for Cytokinetics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Buyback Yield % Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.05 -15.60 -8.02 - -1.98

Cytokinetics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -5.10 -38.78

Competitive Comparison of Cytokinetics's Buyback Yield %

For the Biotechnology subindustry, Cytokinetics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Buyback Yield % falls into.



Cytokinetics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cytokinetics's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 150.602) / 7622.85
=-1.98%

Cytokinetics's annualized Buyback Yield for the quarter that ended in Jun. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 569.667) * 4 / 5876.25
=-38.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jun. 2024) data.


Cytokinetics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics Business Description

Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics Headlines

No Headlines